PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

(2018) Seung Tae Kim et al.   NATURE MEDICINE

Nobel committee honors tumor immunologists

(2018) Anand Rotte et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Cancer immunologists scoop medicine Nobel prize

(2018) Heidi Ledford et al.   NATURE

PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer

(2018) Neda Yaghoubi et al.   BIOMEDICINE & PHARMACOTHERAPY

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

(2017) Paolo A Ascierto et al.   LANCET ONCOLOGY

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?

(2017) Zijun Y. Xu-Monette et al.   Frontiers in Immunology

LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY

(2017) J.S. Weber et al.   ANNALS OF ONCOLOGY

PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy

(2017) Dawn E. Dolan et al.   Cancer Control

PD-1/PD-L and autoimmunity: A growing relationship

(2016) Mohammad Reza Zamani et al.   CELLULAR IMMUNOLOGY

Preliminary results of a phase II study: PD-1 blockade in mismatch repair–deficient, recurrent or persistent endometrial cancer

(2016) A.N. Fader et al.   GYNECOLOGIC ONCOLOGY

Targeting T Cell Co-receptors for Cancer Therapy

(2016) Margaret K. Callahan et al.   IMMUNITY

Immune checkpoint inhibition in ovarian cancer

(2016) Junzo Hamanishi et al.   INTERNATIONAL IMMUNOLOGY

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

(2016) Rita Nanda et al.   JOURNAL OF CLINICAL ONCOLOGY

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

(2016) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

(2016) Alexander M. Lesokhin et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

(2016) Kei Muro et al.   LANCET ONCOLOGY

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

(2016) Howard L Kaufman et al.   LANCET ONCOLOGY

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

(2016) Paul T. Nghiem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model

(2016) Baihao Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

PD-L1 expression in human cancers and its association with clinical outcomes

(2016) Jinming Yu et al.   OncoTargets and Therapy

Regulation of PD-L1: a novel role of pro-survival signalling in cancer

(2015) J. Chen et al.   ANNALS OF ONCOLOGY

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer

(2015) K Abiko et al.   BRITISH JOURNAL OF CANCER

PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer

(2015) Nisha Nagarsheth et al.   CANCER RESEARCH

ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy

(2015) C. Li et al.   EMBO Molecular Medicine

Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort.

(2015) Tanguy Y. Seiwert et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

(2015) Junzo Hamanishi et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors

(2015) Thibault Voron et al.   JOURNAL OF EXPERIMENTAL MEDICINE

NF-κB Regulates PD-1 Expression in Macrophages

(2015) Alexander P. R. Bally et al.   JOURNAL OF IMMUNOLOGY

PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation

(2015) Mei Ji et al.   Journal of Translational Medicine

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

(2015) Antoni Ribas et al.   LANCET ONCOLOGY

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

(2015) Kim C. Ohaegbulam et al.   TRENDS IN MOLECULAR MEDICINE

PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

(2015) Nikolaos Patsoukis et al.   Nature Communications

Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression

(2015) Roberto Bellucci et al.   OncoImmunology

Targeting hypoxia at the forefront of anticancer immune responses

(2015) Muhammad Zaeem Noman et al.   OncoImmunology

Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation

(2014) Miguel F. Sanmamed et al.   CANCER JOURNAL

The Transcription Factor FoxO1 Sustains Expression of the Inhibitory Receptor PD-1 and Survival of Antiviral CD8+ T Cells during Chronic Infection

(2014) Matthew M. Staron et al.   IMMUNITY

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection

(2014) Peiyuan Lu et al.   JOURNAL OF EXPERIMENTAL MEDICINE

RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance

(2014) Yanping Xiao et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

(2014) Muhammad Zaeem Noman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

STAT3, STAT4, NFATc1, and CTCF Regulate PD-1 through Multiple Novel Regulatory Regions in Murine T Cells

(2014) J. W. Austin et al.   JOURNAL OF IMMUNOLOGY

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4+ T cells tolerized by peptide immunotherapy

(2014) Rhoanne C McPherson et al.   eLife

PI3K-delta mediates double-stranded RNA-induced upregulation of B7-H1 in BEAS-2B airway epithelial cells

(2013) Keiko Kan-o et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab

(2013) Jeffrey S. Weber et al.   CANCER

Treg and CTLA-4: Two intertwining pathways to immune tolerance

(2013) Lucy S.K. Walker   JOURNAL OF AUTOIMMUNITY

Ipilimumab-induced acute severe colitis treated by infliximab

(2013) Cecile Pagès et al.   MELANOMA RESEARCH

PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2

(2013) Nikolaos Patsoukis et al.   MOLECULAR AND CELLULAR BIOLOGY

Strength of PD-1 signaling differentially affects T-cell effector functions

(2013) F. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

(2012) Tadashi Yokosuka et al.   JOURNAL OF EXPERIMENTAL MEDICINE

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

(2012) Michael T. McCabe et al.   NATURE

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1

(2012) G. Xiao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation

(2012) N. Patsoukis et al.   Science Signaling

Chronic Virus Infection Enforces Demethylation of the Locus that Encodes PD-1 in Antigen-Specific CD8+ T Cells

(2011) Ben Youngblood et al.   IMMUNITY

IFN-  Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity

(2011) S. Terawaki et al.   JOURNAL OF IMMUNOLOGY

The PD-1 pathway in tolerance and autoimmunity

(2010) Loise M. Francisco et al.   IMMUNOLOGICAL REVIEWS

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD

Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

(2009) Q. Gao et al.   CLINICAL CANCER RESEARCH

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Interferon-λ induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents

(2009) Quanhai Li et al.   EUROPEAN JOURNAL OF CANCER

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

(2009) Loise M. Francisco et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

(2008) Shawn D Blackburn et al.   NATURE IMMUNOLOGY